Evidence map›Paper›PMID 32512228›Full record

ArticleTranslational oncology2020

Low Expression of Smurf1 Enhances the Chemosensitivity of Human Colorectal Cancer to Gemcitabine and Cisplatin in Patient-Derived Xenograft Models.

Jing Guo, Guiying Xu, Chuanbin Mao, Rongfei Wei

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Jing GuoBeijing Municipal Key Laboratory of Advanced Energy Materials and Technology, School of Materials Science and Engineering, University of Science and Technology Beijing, Beijing 100083, China; Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College, Beijing 100021, China; Department of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, OK 73019-5300, USA.
Guiying XuBeijing Municipal Key Laboratory of Advanced Energy Materials and Technology, School of Materials Science and Engineering, University of Science and Technology Beijing, Beijing 100083, China. Electronic address: xugy@mater.ustb.edu.cn.
Chuanbin MaoDepartment of Chemistry and Biochemistry, Stephenson Life Sciences Research Center, University of Oklahoma, 101 Stephenson Parkway, Norman, OK 73019-5300, USA. Electronic address: cbmao@ou.edu.
Rongfei WeiKey Laboratory of Human Disease Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College, Beijing 100021, China; Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Beijing 100021, China; Beijing Key Laboratory for Animal Models of Emerging and Reemerging Infectious, Beijing 100021, China. Electronic address: weirongfei2010@163.com.
University of Science and Technology Beijing · CNInstitute of Laboratory Animal Science · CNUniversity of Oklahoma · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the side effects, chemotherapy is one of the most common treatments in colorectal cancer (CRC). An open-ended question about CRC chemotherapy, which has been discussed quite often, is with respect to the validation of prognostic or predictive factors. It is believed that personalized chemotherapy can improve the treatment outcome of patients with colorectal tumors. Though, Smurf1 is highly expressed in multiple tumors and plays a critical role in the occurrence and development of multiple cancers, it's role in the susceptibility of CRC response to chemotherapy is still unknown, Therefore, the study aimed to understand the role of Smurf1 in the susceptibility of CRC response to chemotherapy. The study showed that the knockdown of Smurf1 increases gemcitabine and cisplatin-induced HCT116 cells apoptosis in vitro. Furthermore, in vivo experiments showed that tumors that had low Smurf1 expression exhibited enhanced gemcitabine, cisplatin, and gemcitabine plus cisplatin anti-tumor effects in HCT116 cell-derived xenograft (CDX) models and patient-derived xenograft (PDX) models. In conclusion, the results indicated that Smurf1 inhibits the chemosensitivity of CRC to gemcitabine, cisplatin, and gemcitabine plus cisplatin. Therefore, downregulati1ng the Smurf1 expression is a potential strategy to increase the efficacy of gemcitabine and cisplatin in CRC patients.

Identifiers

PMID32512228
PMCPMC7281823
OpenAlexW3033003363

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.